Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

BACKGROUND: We examined the impact of race on the maximum tolerated doses (MTD) and final approved doses (FAD) of single-agent molecular-targeted agents (MTA) in North America/Europe (NA/EU) and Asia. METHODS: We searched PubMed and regulatory databases to identify targeted drugs approved globally a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, Tomoya, Bendell, Johanna, LoRusso, Patricia, Tsushima, Takahiro, Desai, Ved, Kenmotsu, Hirotsugu, Watanabe, Junichiro, Ono, Akira, Murugesan, Bhavani, Silva, Joseph, Naito, Tateaki, Greenberg, Jonathan, Kumar, Prasanna, Wang, Yibin, Jikoh, Takahiro, Shiga, Ryota, Hyman, David M., Ho, Alan Loh, Spriggs, David R., Schwartz, Gary K., Gounder, Mrinal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008299/
https://www.ncbi.nlm.nih.gov/pubmed/29795308
http://dx.doi.org/10.1038/s41416-018-0102-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008299/
https://www.ncbi.nlm.nih.gov/pubmed/29795308
http://dx.doi.org/10.1038/s41416-018-0102-1

Ejemplares similares